Literature DB >> 25820333

Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.

Massimiliano Bonifacio1, Gianni Binotto2, Elena Maino3, Elisabetta Calistri4, Luciana Marin5, Luigi Scaffidi6, Luca Frison2, Federico De Marchi5, Mauro Krampera6, Giampiero Semenzato2, Renato Fanin5, Achille Ambrosetti6, Mario Tiribelli5.   

Abstract

Entities:  

Keywords:  discordant response; imatinib-treated CML

Mesh：

Substances：

Year:  2015        PMID： 25820333      PMCID： PMC5004429          DOI： 10.3324/haematol.2015.124685

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Authors:  David Marin; Amr R Ibrahim; Claire Lucas; Gareth Gerrard; Lihui Wang; Richard M Szydlo; Richard E Clark; Jane F Apperley; Dragana Milojkovic; Marco Bua; Jiri Pavlu; Christos Paliompeis; Alistair Reid; Katayoun Rezvani; John M Goldman; Letizia Foroni
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Authors:  B Hanfstein; M C Müller; R Hehlmann; P Erben; M Lauseker; A Fabarius; S Schnittger; C Haferlach; G Göhring; U Proetel; H-J Kolb; S W Krause; W-K Hofmann; J Schubert; H Einsele; J Dengler; M Hänel; C Falge; L Kanz; A Neubauer; M Kneba; F Stegelmann; M Pfreundschuh; C F Waller; S Branford; T P Hughes; K Spiekermann; G M Baerlocher; M Pfirrmann; J Hasford; S Saußele; A Hochhaus
Journal:  Leukemia       Date:  2012-03-26       Impact factor: 11.528

Review 3.  Standardized definitions of molecular response in chronic myeloid leukemia.

Authors:  N C P Cross; H E White; M C Müller; G Saglio; A Hochhaus
Journal:  Leukemia       Date:  2012-04-16       Impact factor: 11.528

4.  Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.

Authors:  Joerg Hasford; Michele Baccarani; Verena Hoffmann; Joelle Guilhot; Susanne Saussele; Gianantonio Rosti; François Guilhot; Kimmo Porkka; Gert Ossenkoppele; Doris Lindoerfer; Bengt Simonsson; Markus Pfirrmann; Rudiger Hehlmann
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

5.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

Authors:  J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

6.  Chronic Myelogenous Leukemia, Version 1.2014.

Authors:  Susan O'Brien; Jerald P Radich; Camille N Abboud; Mojtaba Akhtari; Jessica K Altman; Ellin Berman; Daniel J DeAngelo; Michael Deininger; Steven Devine; Amir T Fathi; Jason Gotlib; Madan Jagasia; Patricia Kropf; Joseph O Moore; Arnel Pallera; Javier Pinilla-Ibarz; Vishnu Vb Reddy; Neil P Shah; B Douglas Smith; David S Snyder; Meir Wetzler; Kristina Gregory; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2013-11       Impact factor: 11.908

Review 7.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

Review 8.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

9.  Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

Authors:  Preetesh Jain; Hagop Kantarjian; Aziz Nazha; Susan O'Brien; Elias Jabbour; Carlos Guillermo Romo; Sherry Pierce; Marylou Cardenas-Turanzas; Srdan Verstovsek; Gautam Borthakur; Farhad Ravandi; Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113
  9 in total
  2 in total

Review 1.  Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Authors:  Naranie Shanmuganathan; Timothy P Hughes
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).

Authors:  Massimo Breccia; Pier Paolo Olimpieri; Odoardo Olimpieri; Fabrizio Pane; Alessandra Iurlo; Paolo Foggi; Alessia Cirilli; Antonietta Colatrella; Marcello Cuomo; Lucia Gozzo; Valentina Summa; Paolo Corradini; Pierluigi Russo
Journal:  Cancer Med       Date:  2020-04-22       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.